Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Total Liabilities (2017 - 2025)

Historic Total Liabilities for Dianthus Therapeutics (DNTH) over the last 8 years, with Q3 2025 value amounting to $31.0 million.

  • Dianthus Therapeutics' Total Liabilities rose 8954.74% to $31.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.0 million, marking a year-over-year increase of 8954.74%. This contributed to the annual value of $21.5 million for FY2024, which is 10437.59% up from last year.
  • As of Q3 2025, Dianthus Therapeutics' Total Liabilities stood at $31.0 million, which was up 8954.74% from $23.0 million recorded in Q2 2025.
  • Dianthus Therapeutics' Total Liabilities' 5-year high stood at $43.2 million during Q1 2022, with a 5-year trough of $4.0 million in Q2 2023.
  • For the 4-year period, Dianthus Therapeutics' Total Liabilities averaged around $19.9 million, with its median value being $16.3 million (2024).
  • In the last 5 years, Dianthus Therapeutics' Total Liabilities tumbled by 8977.26% in 2023 and then skyrocketed by 16626.18% in 2024.
  • Over the past 4 years, Dianthus Therapeutics' Total Liabilities (Quarter) stood at $9.5 million in 2022, then increased by 11.43% to $10.5 million in 2023, then surged by 104.38% to $21.5 million in 2024, then surged by 43.94% to $31.0 million in 2025.
  • Its last three reported values are $31.0 million in Q3 2025, $23.0 million for Q2 2025, and $20.0 million during Q1 2025.